Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the Cambridge, ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nasdaq Global Market closes on ...

At the 2025 Alzheimer’s Association International Conference, one of the bigger splashes was made by an experimental cardiovascular drug. Newamsterdam Pharma Co. NV presented data showing that its ...